AMARIN APPOINTS JOHN F. THERO AS CHIEF FINANCIAL OFFICER

AMARIN APPOINTS JOHN F. THERO AS CHIEF FINANCIAL OFFICER


DUBLIN, Ireland, November 6th, 2009 - Amarin Corporation plc (NASDAQ: AMRN) today announced the appointment of John F. Thero as the Company's Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and administrative matters of the Company and be actively involved in corporate development and other strategic and operational matters. He will report directly to Dr. Declan Doogan, Amarin's interim Chief Executive Officer.
Mr. Thero has more than 20 years of senior financial and operational management experience including over 15 years supporting the growth of life science companies. Previously, Mr. Thero was Chief Financial Officer at ViaCell, Inc., where he helped guide the company to its successful sale, and Abiomed, Inc., during its transition from a development-stage company into a commercial entity. Mr. Thero began his professional career at Arthur Andersen LLP, during which time he became a Certified Public Accountant.


"I am delighted to welcome John to Amarin," said Dr. Doogan. "He brings a wealth of experience and will be a great addition to our management."


Added Mr. Thero, "I am impressed with the clarity of the Company's clinical path and the experience of the Company's AMR101-focused development team. With resources from the Company's recently completed $70 million financing, I look forward to helping move the Company expeditiously through its Phase 3 program."


About Amarin
Amarin is a clinical-stage biopharmaceutical company focused on cardiovascular disease. The Company's lead candidate is AMR101, a prescription grade omega-3 product comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA-E). Amarin is preparing to commence two Phase 3 clinical trials for AMR101 targeting the treatment of hypertriglyceridemia. These trials will be conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). It is estimated that as many as 28 million people in the U.S. alone have elevated blood triglyceride levels, a major risk factor for cardiovascular morbidity and mortality. In addition, Amarin has potential next-generation lipid candidates under evaluation for preclinical development. Amarin recently established its research and development headquarters in Mystic, Connecticut, USA and engaged Medpace as CRO for the Phase 3 trials. In addition to its cardiovascular development focus, Amarin has non-core programs available for partnering in the area of central nervous system (CNS) disorders, including Huntington's disease, myasthenia gravis and Parkinson's disease. Additional information about Amarin is available at www.amarincorp.com

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.